Cardiome Pharma Corp. announced that pursuant to the increase in size of the Board of Directors to six members, as disclosed in the 2014 information circular, an additional director nominee will be included at its 2014 Annual General and Special Meeting of Shareholders held on June 16, 2014. The company announced the nomination of W. James O'Shea to the Board of Directors.

Mr. O'Shea was President and Chief Operating Officer at Sepracor Inc., from October 1999 to March 2007, then a publicly held pharmaceutical company, where he was responsible for successfully building that organization's commercial infrastructure. From April to August 2007, Mr. O'Shea served as Sepracor's Vice Chairman. Prior to Sepracor, Mr. O'Shea was Senior Vice President of Sales and Marketing and Medical Affairs for Zeneca Pharmaceuticals, a business unit of Astra Zeneca Plc.

Mr. O'Shea is past Chairman of the National Pharmaceutical Council and is also a board member of BTG plc, Prostrakan Group Plc, Zalicus Pharmaceuticals and Trevi therapeutics.